Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$69.00 USD

69.00
3,405,133

-0.70 (-1.00%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks News

All You Need to Know About DexCom (DXCM) Rating Upgrade to Strong Buy

DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Benjamin Rains headshot

Profit from Surprise in Q2 2019 Earnings Season

Second quarter 2019 earnings season unofficially starts early next week when the big banks report. So let's take a look at some stocks that could shine for investors...

Urmimala Biswas headshot

Will MedTech Ease Investors' Concern & Outperform? 4 Picks

Lower investment in MedTech might prove to be a concern, more so as gains within this space are staggering.

Sanghamitra Saha headshot

ETF & Stock Winners of Longest US Economic Expansion

The U.S. economy has stepped into the 11th year of the expansion, exhibiting the longest expansion in history. These winning ETFs and stocks will rally further.

Altair Engineering, Netgear, Fitbit, Microsoft and DexCom highlighted as Zacks Bull and Bear of the Day

Altair Engineering, Netgear, Fitbit, Microsoft and DexCom highlighted as Zacks Bull and Bear of the Day

The Zacks Analyst Blog Highlights: JinkoSolar, Salem Media, Ciena, DexCom and Zumiez

The Zacks Analyst Blog Highlights: JinkoSolar, Salem Media, Ciena, DexCom and Zumiez

Benjamin Rains headshot

3 "Internet of Things" Stocks to Buy Right Now

Today we've highlighted three stocks with a Zacks Rank #2 (Buy) or better that could be poised for further IoT-based growth soon.

Sweta Killa headshot

5 Top-Ranked Stocks Crushing the Market in June

Wall Street has staged a nice comeback from the May swoon on hopes of monetary easing policies.

DexCom and Companion Medical Collaboration to Support CGM

The collaboration enables InPen users to display real-time insulin data in Dexcom's (DXCM) CLARITY Diabetes Management Software.

Here's Why You Should Invest in DexCom (DXCM) Stock Now

DexCom (DXCM) is gaining traction from lucrative glucose monitoring market, solid international market presence and strong product portfolio.

Why Is DexCom (DXCM) Down 0.4% Since Last Earnings Report?

DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

DexCom (DXCM) Beats on Q1 Earnings, Hikes '19 Guidance

DexCom's (DXCM) Q1 earnings gain from top-line growth and solid segmental performance. However, contraction in gross margin remains a headwind.

DexCom (DXCM) Reports Q1 Loss, Tops Revenue Estimates

DexCom (DXCM) delivered earnings and revenue surprises of 70.59% and 13.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

DexCom (DXCM) to Report Q1 Earnings: What's in the Offing?

DexCom's (DXCM) G6 censors and lucrative collaborations are likely to drive Q1 results.

DexCom (DXCM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quest Diagnostics (DGX) Q1 Earnings Top Mark, Margins Down

Quest Diagnostics (DGX) currently concentrates on its core diagnostic information services business and tries to maintain discipline in capital deployment.

Abbott (ABT) Q1 Earnings Beat Estimates, Organic Sales Solid

Abbott (ABT) reports strong and consistent EPD and Medical Devices performance organically in Q1.

DexCom (DXCM) Stock Moves 0.35%: What You Should Know

DexCom (DXCM) closed the most recent trading day at $119.30, moving +0.35% from the previous trading session.

DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, DexCom (DXCM) closed at $116.92, marking a -0.2% move from the previous day.

Here's Why You Should Retain ABIOMED Stock in Your Portfolio

Despite cutthroat competition in the niche markets, ABIOMED (ABMD) seems to be well-positioned for growth on strong guidance and solid product portfolio.

Integer Holdings Gets Positive Outlook & B+ Rating From S&P

Integer (ITGR) strengthens its balance sheet by reducing its leverage ratio from 5.6X at the end of 2017 to 3.5X at 2018 end.

Why Veeva Systems (VEEV) is an Attractive Pick Right Now?

Veeva Systems' (VEEV) strong product portfolio is likely to provide it with a competitive edge in the MedTech space.

Here's Why Investors Should Retain NextGen Healthcare Stock

Despite aggressive rivalry in the niche space, NextGen (NXGN) will continue to benefit from strong demand for its other NextGen solutions that include Hospitals, EHR and practice management.

Varian Medical (VAR) Collaborates With Korea-Based Hospital

Varian Medical (VAR) has seen notable developments in Asia of late.

Allscripts' FollowMyHealth Partners Ephraim McDowell Health

Allscripts' (MDRX) FollowMyHealth is an EHR-neutral patient engagement platform that allows patients to stay connected with their physicians.